XML 17 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 37,967 $ 59,640
Short-term investments 314,600 329,462
Accounts receivable, net 3,314 15,678
Inventory 13,654 11,109
Other current assets 13,260 10,063
Total current assets 382,795 425,952
Long-term investments 59,596 0
Property, plant and equipment, net 62,396 65,601
Goodwill 76,501 76,501
Other assets 767 817
Total assets 582,055 568,871
Current liabilities:    
Accounts payable 8,563 2,816
Accrued compensation 19,088 18,280
Accrued clinical trial expenses 7,000 7,958
Other accrued expenses 9,302 4,711
Interest payable 4,198 4,198
Capital lease obligations, current portion 2,482 2,908
Liability related to refundable upfront payment 12,500 12,500
Deferred revenue, current portion 25,491 14,352
Other current liabilities 3,920 4,499
Total current liabilities 92,544 72,222
Senior secured notes, net 244,771 243,464
Liability related to the sale of future royalties, net 98,394 105,950
Deferred revenue, less current portion 56,225 51,887
Other long-term liabilities 5,959 7,223
Total liabilities 497,893 480,746
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at September 30, 2017 or December 31, 2016 0 0
Common stock, $0.0001 par value; 300,000 shares authorized; 156,953 shares and 153,212 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively 15 15
Capital in excess of par value 2,170,169 2,111,483
Accumulated other comprehensive loss (1,907) (2,363)
Accumulated deficit (2,084,115) (2,021,010)
Total stockholders’ equity 84,162 88,125
Total liabilities and stockholders’ equity $ 582,055 $ 568,871